



# Therapeutic Effects of Photobiomodulation Therapy on Multiple Sclerosis by Regulating the Inflammatory Process and Controlling Immune Cell Activity: A Novel Promising Treatment Target

Saeed Vafaei-Nezhad<sup>1,2</sup>, Somayeh Niknazar<sup>3,4</sup>, Ali Asghar Payvandi<sup>4</sup>, Atefeh Shirazi Tehrani<sup>5</sup>, Navid Ahmady Roozbahany<sup>4</sup>, Behnaz Ahrabi<sup>2,5</sup>, Hojjat Allah Abbaszadeh<sup>4,2\*</sup>, Shahram Darabi<sup>6\*</sup>

<sup>1</sup>Department of Anatomical Sciences, School of Medicine, Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran

<sup>2</sup>Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>3</sup>Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>4</sup>Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>5</sup>Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>6</sup>Cellular and Molecular Research Center, Research Institute for Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran

## \*Correspondence to

Hojjat Allah Abbaszadeh, Hearing Disorders Research Center, Loghman Hakim Hospital; Email: [dr.abbaszadeh79@gmail.com](mailto:dr.abbaszadeh79@gmail.com)

Shahram Darabi, Cellular and Molecular Research Center, Research Institute for Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran; Email: [shahram2005d@yahoo.com](mailto:shahram2005d@yahoo.com)

Received: April 29, 2022

Accepted: June 25, 2022

Published online July 27, 2022



## Abstract

**Introduction:** Multiple sclerosis (MS) is one of the autoimmune and chronic diseases of the central nervous system; this disease occurs more frequently in young people and women and leads to neurological symptoms. Oxidative stress, inflammatory processes, and oligodendrocyte dysfunction have a pivotal role in the pathophysiology of this disease. Nowadays it is reported that photobiomodulation (PBM) as a non-invasive treatment has neuroprotective potential, but the exact mechanisms are not understood.

**Methods:** In this study, we reviewed the effects of PBM on MS. In this regard, we used the keywords "Photobiomodulation", "Laser therapy", and "Low-level laser therapy" on MS to find related studies on this subject in PubMed, Google scholar, Elsevier, Medline, and Scopus databases.

**Results:** PBM has positive effects on MS by regulating the inflammatory process, controlling immune cell activity and mitochondrial functions, as well as inhibiting free radicals production which finally leads to a reduction in neurological defects and an improvement in the functional status of patients.

**Conclusion:** Overall, researchers have suggested the use of laser therapy in neurodegenerative diseases due to its numerous therapeutic effects.

**Keywords:** Multiple sclerosis; Photobiomodulation, Myelin, Central nervous system

## Introduction

Neurodegeneration disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) and multiple sclerosis (MS), spinal cord injury (SCI), and COVID 19 are usually progressive diseases that cause structural and cellular changes in the nervous system, eventually leading to symptoms such as cognitive, motor, and memory impairments.<sup>1-5</sup> Today, researchers have used a variety of treatments including drugs and cell therapy to minimize the complications of diseases.<sup>6,7</sup> Since photobiomodulation (PBM) is a non-invasive method, it has received more attention.<sup>8</sup> The pathophysiology of these diseases is

often multifactorial and the exact mechanisms are not understood yet. MS is a chronic and inflammatory disease of the central nervous system in which the myelin sheath of the neural cells is damaged through a combination of immune dysregulation and oligodendrocyte dysfunction.<sup>9</sup> Due to its severe and debilitating effects, as well as the imposition of high medical costs, this disease has had wide social and economic effects on the patients.<sup>10</sup> It is well documented that invasion of T helper lymphocytes (CD4+) into neural tissue plays an important role at the onset of this disease.<sup>11,12</sup> Despite many studies in this field, the exact mechanism of the onset and progression of this

disease is unknown. However, researchers have suggested that the lack of control of immune system cells, as well as the dysfunction of oligodendrocytes, could be the main causes of the disease. Axonal disruption, programmed cell death, and impaired neurotransmitter transmission have also been reported in the disease.<sup>9,11,12</sup> In previous studies, it was well established that in the neuroinflammation condition, the level of production of active oxygen and nitrogen species is significantly increased, which can lead to the disruption of the antioxidant system.<sup>12</sup> Elevated levels of these factors can eventually lead to the widespread destruction of vital cell components such as DNA, lipids, proteins, and mitochondria. Nowadays, there is ample evidence that free radicals play a key role in the progression of MS.<sup>13</sup> Studies have shown that neutrophils and lymphocytes (Th1, Th17, Th22), as well as lymphocytes T CD8, B cells, and macrophages, become activated in this disease, which can lead to the overproduction of inflammatory cytokines, active oxygen and nitrogen species against myelin antigens.<sup>11,14-16</sup> In addition, it has been shown that the activity of regulatory lymphocytes (CD4+CD25+Treg) is also impaired in this disease. These factors, in turn, can increase damage to the neural tissue.<sup>17,18</sup> Today, MS treatments focus more on the anti-inflammatory and immune-regulating process. Previous studies have implicated the production of oxidative stress related to mitochondrial dysfunction, which plays an important role in the chronic phase of MS.<sup>10,19,20</sup>

It has been demonstrated that PBM is associated with neuroprotective effects that can mitigate neurological symptoms in neurological disorders through a variety of mechanisms.<sup>21-23</sup> It is well documented that PBM can enhance neuronal regeneration and also induce Schwann cell proliferation and viability of oligodendrocytes in the CNS.<sup>24,25</sup> In the animal model of brain injury, PBM administration could decrease neural cell apoptosis, enhance neural survival, and raise the production of BDNF as a growth factor.<sup>26-28</sup> The beneficial effects of PBM in animal models of SCI have previously been reported.<sup>8,29,30</sup> It was revealed that in the contusion model of SCI, PBM-treated groups showed a significant down-regulation of some oxidant factors such as catalase (CAT), malondialdehyde (MDA), superoxide dismutase (SOD), pro-inflammatory cytokines (TNF- $\alpha$ , IL-1 $\beta$ ), and apoptosis-related marker (caspase-3). Furthermore, a considerable increase in glutathione peroxidase (GSH-PX) and anti-inflammatory factors (IL-10) has been reported.<sup>31</sup>

Researchers proposed that PBM could improve functional recovery and decrease neurological impairment by controlling inflammation processes and oxidative stress.<sup>31,32</sup> In addition, it has been shown that PBM can prevent the overproduction of inflammatory factors and free radicals by affecting immune system cells at the site

of damage to the nervous system (resident and migrating cells) and regulating their activity which can inhibit the destruction of axonal myelin and neural apoptosis.<sup>33,34</sup> Mitochondrial dysfunction is considered to be one of the main mediators of the pathogenesis and progression of neurodegenerative diseases.<sup>35</sup> In this regard, PBM can also directly affect mitochondrial function (especially cytochrome c), leading to increased ATP production and a reduction in nitric oxide (NO) and oxidative markers at the site of injury.<sup>36-39</sup>

### **Photobiomodulation Therapy on Multiple Sclerosis**

PBM therapy has been used in several experimental animal disease models. Today, the use of PBM to treat many diseases such as osteoporosis, wound healing, muscle problems, inflammatory pain, periodontal diseases, lung inflammation, nervous system injuries and autoimmune diseases is in the spotlight as a non-invasive treatment.<sup>23,27,40-44</sup> PBM have been well documented in previous studies to have beneficial therapeutic effects on neurodegenerative diseases such as SCI, stroke, and traumatic brain injury.<sup>8,21,31</sup> The researchers of these studies have mentioned that PBM is a promising and novel treatment that can reduce neurological complications. Despite many studies in this field, the exact mechanism of the therapeutic effect of PBM on neurodegenerative diseases is still poorly understood. Several studies have shown that PBM has neuroprotective potential.<sup>8,29,30</sup> However, researchers have suggested that the use of PBM in nervous system disorders can reduce apoptosis and autophagy, inhibit free radicals production, decrease inflammatory factors, and ultimately significantly reduce the affected area. In addition, it has been shown that PBM improve axonal restoration, increase neurogenesis, stimulate angiogenesis and the production of anti-inflammatory factors, and cause mitochondrial respiration enhancement and neural cell survival.<sup>21-23,44,45</sup> Studies have shown that low-level laser radiation (red or near-infrared light) can be absorbed by cytochrome c oxidase (mitochondrial chromophore structures), ultimately leading to increased ATP production and cellular respiration, and it can also modulate the production of free radicals and NO.<sup>46</sup> In this regard, some researcher examined the effect of PBM (AlGaInP, 660 nm, and GaAs, 904 nm) in an animal model of MS (experimental autoimmune encephalomyelitis). The results of their study revealed that laser therapy was able to significantly reduce NO expression. Also, they observed a significant reduction in the level of inflammatory markers such as IL-17, IFN- $\gamma$ , and IL-1 $\beta$ . In addition, histological data showed that this treatment reduced neuroinflammation by acting on lymphocytes and ultimately reduced demyelination.<sup>47</sup> Recent clinical studies in MS patients have reported promising therapeutic effects of PBM. The data from these studies

**Table 1.** Some Studies About the Effect of PBM on MS

Author	Year	Title	Length of Radiation
Muili et al <sup>49</sup>	2012	Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by photobiomodulation induced by 670 nm light	(GaAlA) LED arrays (75 cm <sup>2</sup> ) of 670 nm
Goncalves et al <sup>47</sup>	2016	Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis	AlGaInP, 660 nm, GaAs, 904 nm
Kubsik et al <sup>48</sup>	2016	Application of laser radiation and magnetostimulation in the treatment of patients with multiple sclerosis	Wavelengths 650 nm and of power 50 mW
Duarte et al <sup>9</sup>	2018	Low-level laser therapy modulates demyelination in mice	(GaAlA) 36 J/cm <sup>2</sup> , 50 mW, 0.028 cm <sup>2</sup>
Silva et al <sup>19</sup>	2020	Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis–Randomized clinical trial	wavelength: 808 nm; power output: 100 mW

clearly demonstrated that PBM was able to significantly increase IL-10 levels, improve motor recovery and functional status of patients, enhance the quality of life, and significantly reduce pain in these patients.<sup>19,48</sup> Researchers have determined that the main pathological causes of MS are a combination of inflammatory factors and mitochondrial dysfunction. The results of this studies showed that PBM was able to significantly reduce levels of pro-inflammatory factors (IFN- $\gamma$ , TNF- $\alpha$ ) but increased levels of anti-inflammatory factors (IL-10, IL-4). Researchers suggested that PBM might slow disease progression by regulating inflammatory processes.<sup>49</sup> In another study, researchers used cuprizone (a classic model of demyelination) to induce the animal model of MS. The results of this study indicated that PBM could improve motor performance, decrease demyelination, raise the number of oligodendrocyte precursor cells, and regulate astrocyte and microglia activation<sup>9</sup> (Table 1).

## Discussion

Various studies have proved the positive therapeutic effect of PBM therapy on different diseases. Since laser treatment is a non-invasive procedure, researchers suggest it is a promising treatment for neurological disorders such as SCI, AD, HD, and MS.<sup>50-52</sup> Hence, extensive research has been conducted in this field. However, the exact mechanism of PBM is still poorly understood and needs further investigation. The results of the studies suggest that PBM can affect various cellular functions such as cell survival, apoptosis, ATP production, autophagy, production of growth factors, and inflammatory processes.<sup>21,41,52,53</sup> Previous studies have widely demonstrated the neuroprotective potential of laser radiations. Based on the results of these studies, researchers have suggested the use of PBM in neurodegenerative diseases can reduce symptoms and neurological defects through the inhibition of cell programming death, suppression of autophagy, improvement of mitochondrial function, increase of ATP production, regulation of inflammatory cell activity, and control of the inflammatory process.<sup>21,38,51</sup> In addition, it has been found that the use of PBM along with other common treatments has increased the effectiveness of

these treatments.<sup>29,54</sup> Some recent studies showed that PBM causes an increase in neuronal growth factors as well as an improvement in remyelination in some animal models of neurodegenerative diseases.<sup>10,55</sup>

## Conclusion

According to the results of previous studies, since many of them show positive effects of PBM on neurodegenerative diseases, particularly MS, nowadays the bulk of studies suggest that PBM can be a novel and promising treatment, in a safe and non-invasive manner, for MS patients.

## Acknowledgment

We are thankful for the funding provided by the Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

## Conflict of Interests

The authors declare that they have no conflict of interest

## Ethical Considerations

All protocols were confirmed by the Ethics Committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.REC.1400.009).

## References

1. Kumar A, Singh A. A review on Alzheimer's disease pathophysiology and its management: an update. *Pharmacological reports*. 2015;67(2):195-203.
2. Darabi S, Noori-Zadeh A, Rajaei F, Abbaszadeh HA, Bakhtiyari S, Roozbahany NA. SMER28 attenuates dopaminergic toxicity mediated by 6-hydroxydopamine in the rats via modulating oxidative burdens and autophagy-related parameters. *Neurochemical Research*. 2018 Dec;43(12):2313-23.
3. Boroujeni ME, Simani L, Bluysen HA, Samadikhah HR, Zamanlui Benisi S, Hassani S, Akbari Dilmaghani N, Fathi M, Vakili K, Mahmoudiasl GR, Abbaszadeh HA. Inflammatory response leads to neuronal death in human post-mortem cerebral cortex in patients with COVID-19. *ACS Chemical Neuroscience*. 2021 Jun 8;12(12):2143-50.
4. Vafaei-Nezhad S, Niknazar S, Norouzian M, Abdollahifar M-A, Aliaghaei A, Abbaszadeh HA. Therapeutics effects of [Pyr1] apelin-13 on rat contusion model of spinal cord injury: An experimental study. *Journal of Chemical Neuroanatomy*. 2021;113:101924.
5. Dargahi N, Katsara M, Tselios T, Androutsou M-E, De Courten M, Matsoukas J, et al. Multiple sclerosis: immunopathology and treatment update. *Brain sciences*. 2017;7(7):78.
6. Peyvandi AA, Roozbahany NA, Peyvandi H, Abbaszadeh HA, Majdinasab N, Faridan M, Niknazar S. Critical role

- of SDF-1/CXCR4 signaling pathway in stem cell homing in the deafened rat cochlea after acoustic trauma. *Neural regeneration research*. 2018 Jan;13(1):154.
7. Boroojen FR, Mashayekhan S, Abbaszadeh HA. The controlled release of dexamethasone sodium phosphate from bioactive electrospun PCL/gelatin nanofiber scaffold. *Iranian Journal of Pharmaceutical Research: IJPR*. 2019;18(1):111.
  8. Vafaei-Nezhad S, Hassan MP, Noroozian M, Aliaghaei A, Tehrani AS, Abbaszadeh HA, Khoshirsat S. A review of low-level laser therapy for spinal cord injury: challenges and safety. *Journal of Lasers in Medical Sciences*. 2020;11(4):363.
  9. Duarte KCN, Soares TT, Magri AMP, Garcia LA, Le Sueur-Maluf L, Renno ACM, et al. Low-level laser therapy modulates demyelination in mice. *Journal of Photochemistry and Photobiology B: Biology*. 2018;189:55-65.
  10. Meamar R, Nematollahi S, Dehghani L, Mirmosayyeb O, Shayegannejad V, Basiri K, et al. The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies. *Advanced Biomedical Research*. 2016;5.
  11. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. *Brain pathology*. 2007;17(2):210-8.
  12. Sospedra M, Martin R, editors. *Immunology of multiple sclerosis*. Seminars in neurology; 2016: Thieme Medical Publishers.
  13. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. *Investigative ophthalmology & visual science*. 2007;48(2):681-91.
  14. Hossein-khannazer N, Shabani S, Farokhfard M, Azizi G, Asarzadegan F, Safarpour Lima B, et al. Pivotal cytokines and their transcription factors are the targets of galuronic acid (G2013) for inhibiting the immunopathogenesis process of multiple sclerosis. *Drug Development Research*. 2020;81(4):511-6.
  15. Hemmer B, Archelos JJ, Hartung H-P. New concepts in the immunopathogenesis of multiple sclerosis. *Nature Reviews Neuroscience*. 2002;3(4):291-301.
  16. Hossein-Khannazer N, Zian Z, Bakkach J, Kamali AN, Hosseinzadeh R, Anka AU, et al. Features and roles of T helper 22 cells in immunological diseases and malignancies. *Scandinavian journal of immunology*. 2021;93(5):e13030.
  17. Venken K, Hellings N, Broekmans T, Hensen K, Rummens J-L, Stinissen P. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. *The Journal of Immunology*. 2008;180(9):6411-20.
  18. Haas J, Fritzsching B, Trübswetter P, Korporal M, Milkova L, Fritz B, et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. *The Journal of Immunology*. 2007;179(2):1322-30.
  19. Silva T, Fragoso YD, Destro Rodrigues MFS, Gomes AO, da Silva FC, Andreo L, et al. Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis—Randomized clinical trial. *PLoS one*. 2020;15(4):e0230551.
  20. Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. *Annals of neurology*. 2006;59(3):478-89.
  21. Bathini M, Raghushaker CR, Mahato KK. The molecular mechanisms of action of photobiomodulation against neurodegenerative diseases: a systematic review. *Cellular and Molecular Neurobiology*. 2020:1-17.
  22. Gao X, Xing D. Molecular mechanisms of cell proliferation induced by low power laser irradiation. *Journal of biomedical science*. 2009;16(1):1-16.
  23. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. *AIMS biophysics*. 2017;4(3):337.
  24. Rojas JC, Lee J, John JM, Gonzalez-Lima F. Neuroprotective effects of near-infrared light in an in vivo model of mitochondrial optic neuropathy. *Journal of Neuroscience*. 2008;28(50):13511-21.
  25. Oron A, Oron U, Chen J, Eilam A, Zhang C, Sadeh M, et al. Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. *Stroke*. 2006;37(10):2620-4.
  26. Leung MC, Lo SC, Siu FK, So KF. Treatment of experimentally induced transient cerebral ischemia with low energy laser inhibits nitric oxide synthase activity and up-regulates the expression of transforming growth factor-beta 1. *Lasers in Surgery and Medicine: The Official Journal of the American Society for Laser Medicine and Surgery*. 2002;31(4):283-8.
  27. Thunshelle C, Hamblin MR. Transcranial low-level laser (light) therapy for brain injury. *Photomedicine and laser surgery*. 2016;34(12):587-98.
  28. Xuan W, Agrawal T, Huang L, Gupta GK, Hamblin MR. Low-level laser therapy for traumatic brain injury in mice increases brain derived neurotrophic factor (BDNF) and synaptogenesis. *Journal of biophotonics*. 2015;8(6):502-11.
  29. Sarveazad A, Janzadeh A, Taheripak G, Dameni S, Yousefifard M, Nasirinezhad F. Co-administration of human adipose-derived stem cells and low-level laser to alleviate neuropathic pain after experimental spinal cord injury. *Stem cell research & therapy*. 2019;10(1):1-15.
  30. Kim J, Kim E-H, Lee K, Kim Y, Na SH, et al. Low-level laser irradiation improves motor recovery after contusive spinal cord injury in rats. *Tissue engineering and regenerative medicine*. 2017;14(1):57-64.
  31. Hassan MP, Abdollahifar M-A, Aliaghaei A, Tabeie F, Vafaei-Nezhad S, Noroozian M, et al. Photobiomodulation therapy improved functional recovery and overexpression of interleukins-10 after contusion spinal cord injury in rats. *Journal of Chemical Neuroanatomy*. 2021;117:102010.
  32. Torres S, De Sanctis J, de Briceno L, Hernandez N, Finol H. Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. *Journal of Endocrinology*. 2004;181(3):419-27.
  33. Song S, Zhou F, Chen WR. Low-level laser therapy regulates microglial function through Src-mediated signaling pathways: implications for neurodegenerative diseases. *Journal of neuroinflammation*. 2012;9(1):1-17.
  34. Yun Y-C, Jang D, Yoon S-B, Kim D, Choi D-H, Kwon O, et al. Laser acupuncture exerts neuroprotective effects via regulation of Creb, Bdnf, Bcl-2, and Bax gene expressions in the hippocampus. *Evidence-Based Complementary and Alternative Medicine*. 2017;2017.
  35. Cerella C, Diederich M, Ghibelli L. The dual role of calcium as messenger and stressor in cell damage, death, and survival. *International journal of cell biology*. 2010;2010.
  36. Lapchak PA, De Taboada L. Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5'-triphosphate (ATP) content following embolic strokes in rabbits. *Brain research*. 2010;1306:100-5.
  37. Huang YY, Nagata K, Tedford CE, McCarthy T, Hamblin MR. Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro. *Journal of biophotonics*. 2013;6(10):829-38.
  38. Karu TI, Pyatibrat LV, Kalendo GS. Photobiological

- modulation of cell attachment via cytochrome c oxidase. *Photochemical & Photobiological Sciences*. 2004;3(2):211-6.
39. Wang R, Dong Y, Lu Y, Zhang W, Brann DW, Zhang Q. Photobiomodulation for global cerebral ischemia: targeting mitochondrial dynamics and functions. *Molecular neurobiology*. 2019;56(3):1852-69.
  40. de Souza Costa M, de Brito TV, de Oliveira SB, Souza Brauna ID, Neto JC, Teles RH, Dutra YM, de Aguiar Magalhães D, Sousa SG, de Sousa JA, Branco CE. Photobiomodulation exerts anti-inflammatory effects on the vascular and cellular phases of experimental inflammatory models. *Lasers in Medical Science*. 2022 Feb;37(1):563-71.
  41. Mohsenifar Z, Fridoni M, Ghatrehsamani M, Abdollahifar M-a, Abbaszadeh H, Mostafavinia A, et al. Evaluation of the effects of pulsed wave LLLT on tibial diaphysis in two rat models of experimental osteoporosis, as examined by stereological and real-time PCR gene expression analyses. *Lasers in medical science*. 2016;31(4):721-32.
  42. Rochkind S, Rousso M, Nissan M, Villarreal M, Barr-Nea L, Rees D. Systemic effects of low-power laser irradiation on the peripheral and central nervous system, cutaneous wounds, and burns. *Lasers in surgery and medicine*. 1989;9(2):174-82.
  43. Tolentino M, Lyons J. Photobiomodulation for multiple sclerosis in animal models. *Photobiomodulation in the Brain*: Elsevier; 2019. p. 241-51.
  44. Aimbire F, Santos F, Albertini R, Castro-Faria-Neto H, Mittmann J, Pacheco-Soares C. Low-level laser therapy decreases levels of lung neutrophils anti-apoptotic factors by a NF- $\kappa$ B dependent mechanism. *International immunopharmacology*. 2008;8(4):603-5.
  45. Svobodova B, Kloudova A, Ruzicka J, Kajtmanova L, Navratil L, Sedlacek R, et al. The effect of 808 nm and 905 nm wavelength light on recovery after spinal cord injury. *Scientific reports*. 2019;9(1):1-14.
  46. Chen AC, Arany PR, Huang Y-Y, Tomkinson EM, Sharma SK, Kharkwal GB, et al. Low-level laser therapy activates NF- $\kappa$ B via generation of reactive oxygen species in mouse embryonic fibroblasts. *PloS one*. 2011;6(7):e22453.
  47. Goncalves ED, Souza PS, Lieberknecht V, Fidelis GS, Barbosa RI, Silveira PC, et al. Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis. *Autoimmunity*. 2016;49(2):132-42.
  48. Kubsik A, Klimkiewicz R, Janczewska K, Klimkiewicz P, Jankowska A, Woldańska-Okońska M. Application of laser radiation and magnetostimulation in therapy of patients with multiple sclerosis. *NeuroRehabilitation*. 2016;38(2):183-90.
  49. Muili KA, Gopalakrishnan S, Meyer SL, Eells JT, Lyons J-A. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by photobiomodulation induced by 670 nm light. *PloS one*. 2012;7(1):e30655.
  50. Berman MH, Nichols TW. Treatment of neurodegeneration: integrating Photobiomodulation and neurofeedback in Alzheimer's dementia and Parkinson's: a review. *Photobiomodulation, photomedicine, and laser surgery*. 2019;37(10):623-34.
  51. Lim S, editor Analysis of photobiomodulation therapy conditions used to treat neurodegenerative brain diseases. *Mechanisms and Techniques in Photodynamic Therapy and Photobiomodulation*; 2021: International Society for Optics and Photonics.
  52. Foo ASC, Soong TW, Yeo TT, Lim K-L. Mitochondrial dysfunction and Parkinson's disease—Near-infrared photobiomodulation as a potential therapeutic strategy. *Frontiers in Aging Neuroscience*. 2020;12:89.
  53. Yang L, Youngblood H, Wu C, Zhang Q. Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation. *Translational neurodegeneration*. 2020;9(1):1-22.
  54. Abdallah AN, Shamaa AA, El-Tookhy OS. Evaluation of treatment of experimentally induced canine model of multiple sclerosis using laser activated non-expanded adipose derived stem cells. *Research in veterinary science*. 2019;125:71-81.
  55. Tolentino M, Cho CC, Lyons JA. Photobiomodulation Modulates Interleukin-10 and Interferon Gamma Production by Mononuclear Cells from Healthy Donors and Persons with Multiple Sclerosis. *Photobiomodulation, Photomedicine, and Laser Surgery*. 2022 Apr 1;40(4):234-44.